Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Recruiting Observational Study
Lung Cancer - Non Small Cell EGFR Exon 19 Deletion Mutation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Female
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Our Lady of the Lake Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their g…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18-100 years old * Biologically born female * Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group) * No cancer diagnosis (Arm 2-health control) Exclusion Criteria: * less than 18 years of age * Biologically born male * Incarcerated at the time of participation
Contacts

Cynthia Knox, MBA

225-765-3344

Cynthia.Knox@fmolhs.org

CONTACT

Christine LeBoeuf, DNP

225-763-5956

Christine.Leboeuf@fmolhs.org

CONTACT